Search

AstraZeneca PLC

Open

SectorHealthcare

10,470 1.55

Overview

Share price change

24h

Current

Min

10282

Max

10502

Key metrics

By Trading Economics

Income

237M

1.7B

Sales

1.3B

15B

P/E

Sector Avg

29.777

57.333

EPS

2.09

Dividend yield

2.43

Profit margin

11.188

Employees

94,300

EBITDA

-235M

4.4B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+30.3% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.43%

2.63%

Next Earnings

29 kwi 2025

Market Stats

By TradingEconomics

Market Cap

-19B

157B

Previous open

10468.45

Previous close

10470

AstraZeneca PLC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 mar 2025, 03:15 UTC

Major Market Movers

Harbour BioMed Shares Soar on News of AstraZeneca Collaboration

17 mar 2025, 07:42 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio

15 kwi 2025, 09:55 UTC

Market Talk

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

9 kwi 2025, 07:23 UTC

Market Talk

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

3 kwi 2025, 08:41 UTC

Market Talk

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3 kwi 2025, 08:36 UTC

Market Talk

U.K. Pharma to Have Some Share-Price Volatility But Long-Term Outlook Remains Intact -- Market Talk

3 kwi 2025, 07:51 UTC

Market Talk

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

31 mar 2025, 09:31 UTC

Hot Stocks

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

17 mar 2025, 14:43 UTC

Market Talk

AstraZeneca's Latest Rare-Disease Drug Results Slightly Disappoint, Barclays Says -- Market Talk

17 mar 2025, 13:55 UTC

Market Talk
Acquisitions, Mergers, Takeovers

AstraZeneca's EsoBiotec Deal Seen as Logical -- Market Talk

17 mar 2025, 07:04 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca: Transaction Doesn't Affect Fincl Guidance for 2025.

17 mar 2025, 07:03 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca: Acquisition Expected to Close in 2Q 2025

17 mar 2025, 07:03 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca to Pay Up to $575M Upon Development, Regulatory Milestones Being Met

17 mar 2025, 07:01 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca to Make Initial Payment of $425M on Deal Closing

17 mar 2025, 07:01 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca Buying EsoBiotec for up to $1B

17 mar 2025, 07:01 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca to Buy EsoBiotec to Advance Cell Therapy Ambition

17 mar 2025, 07:00 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca to Buy EsoBiotec

28 lut 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

26 lut 2025, 14:59 UTC

Market Talk

AstraZeneca's Breast-Cancer Drug Results Seen as Positive Surprise -- Market Talk

26 lut 2025, 08:04 UTC

Market Talk
Earnings

AstraZeneca's Cancer Drug Pipeline Could Fuel $80 Billion Sales Target -- Market Talk

20 lut 2025, 11:34 UTC

Acquisitions, Mergers, Takeovers

FibroGen: Co. Maintains Its Rights to Roxadustat in U.S. and in All Markets Not Licensed to Astellas >FGEN

20 lut 2025, 11:34 UTC

Acquisitions, Mergers, Takeovers

FibroGen: Upon Closing, AstraZeneca Will Obtain All Rights to Roxadustat in China >FGEN

20 lut 2025, 11:33 UTC

Acquisitions, Mergers, Takeovers

FibroGen: Following Close of Transaction, Co. Will Repay Term Loan Facility to Investment Funds Managed by Morgan Stanley Tactical Value >FGEN

20 lut 2025, 11:33 UTC

Acquisitions, Mergers, Takeovers

FibroGen; Will Receive Enterprise Value of $85M Plus FibroGen Net Cash Held in China at Closing, Currently Estimated to Be About $75M >FGEN

20 lut 2025, 11:31 UTC

Acquisitions, Mergers, Takeovers

FibroGen: To Continue to Advance Its Oncology Pipeline, With Initiation of Phase 2 Monotherapy Trial of FG-3246 in Metastatic Castration-Resistant Prostate Cancer in 2Q 2025 >FGEN

20 lut 2025, 11:30 UTC

Acquisitions, Mergers, Takeovers

FibroGen Announces Sale of FibroGen China to AstraZeneca for About $160M

13 lut 2025, 10:49 UTC

Market Talk
Earnings

AstraZeneca Stands Out With Catalyst-Rich, Diversified Pipeline -- Market Talk

7 lut 2025, 10:30 UTC

Top News

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6 lut 2025, 15:18 UTC

Market Talk

U.K. Health System Needs to Improve Investment Environment, AstraZeneca CEO Says -- Market Talk

6 lut 2025, 13:24 UTC

Market Talk

AstraZeneca's Increased R&D Spend Is a Positive -- Market Talk

AstraZeneca PLC Forecast

Price Target

By TipRanks

30.3% upside

12 Months Forecast

Average 13,501.38 GBX  30.3%

High 17,200 GBX

Low 10,900 GBX

Based on 15 Wall Street analysts offering 12 month price targets forAstraZeneca PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

15 ratings

11

Buy

4

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.